125469 Apr 2026

: Recent 2024 reviews led to labeling updates regarding risks for patients undergoing surgeries requiring general anesthesia, as well as the addition of "dysgeusia" (taste distortion) as a potential side effect. Other Potential Matches

: The drug was not referred to an advisory committee because its safety profile was similar to other approved drugs in its class and didn't raise unexpected issues. 125469

While the pharmaceutical review is the most prominent, the number may also refer to: CDTL Review and Division Summary Memo for Regulatory Action : Recent 2024 reviews led to labeling updates